Arrowhead to Present at Upcoming Scientific Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate" (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at upcoming scientific conferences.
Scheduled conference presentations in May include the following:
15th Annual North American TIDES Conference - Boston, MA, USA, May 12-15, 2013
May 14, 2013 - An oral presentation titled, Development of DPC Technology for Therapeutic siRNA Delivery, will be presented by David Lewis, Ph.D., Vice President, Biology;
May 15, 2013 - An oral presentation titled, Co-injection of a Targeted, Reversibly Masked Endosomolytic Polymer Dramatically Improves the Efficacy of Small Interfering RNA-Conjugates In Vivo, will be presented by David B. Rozema, Ph.D., Vice President, Chemistry;
Digestive Disease Week 2013 Orlando, FL, USA, May 18-21, 2013
May 18, 2013 - A poster presentation titled, Long duration of effect from an RNAi therapeutic to treat chronic hepatitis B virus infection correlates with persistence of the phosphorylated guide strand, will be presented by Christine Wooddell, Ph.D., Senior Scientist.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.
For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to email@example.com
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Source: Arrowhead Research CorporationCopyright Business Wire 2013